Form 4: Medifast CFO James P. Maloney Receives Stock Grant

Medifast's Chief Financial Officer, James P. Maloney, reports the acquisition of 8,718 shares of common stock through a restricted stock unit grant.

Summary

• On March 13, 2024, James P. Maloney, the Chief Financial Officer of Medifast, Inc., acquired 8,718 shares of common stock.
• This acquisition was a grant of restricted stock units under the 2012 Share Incentive Plan.
• The restricted stock units will vest in three equal annual installments, starting on the first anniversary of the grant date.
• Each restricted stock unit represents the right to receive one share of Medifast's common stock.
• Following the transaction, Maloney beneficially owns 20,150 shares of Medifast common stock.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding executive compensation, with a neutral to slightly positive sentiment due to the alignment of management and shareholder interests.

Positives

• The grant of restricted stock units aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The restricted stock units will vest in three equal annual installments beginning on the first anniversary of the grant date.

Industry Context

Stock grants are a common form of executive compensation in publicly traded companies, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including stock grants, are typical in publicly traded companies like Medifast to incentivize performance and retain key personnel.
• Comparing the size and vesting schedule of this grant to similar companies in the weight management and direct selling industries (e.g., Herbalife, Nu Skin) would provide a benchmark for its competitiveness.

Stakeholder Impact

• Shareholders may view the stock grant positively as it incentivizes the CFO to focus on long-term value creation.
• Employees may see the grant as a sign of the company's commitment to its leadership team.

Key Dates